RESUMEN
In this study, we demonstrate improved photovoltaic properties in inverted organic thin-film solar cells by simultaneous excitation of grating-coupled surface plasmons and grating-coupled waveguide modes on gold grating surfaces. The cell consists of a glass-ITO substrate/titanium dioxide/poly(3-hexylthiophene-2,5-diyl):phenyl-C61-butyric acid methyl ester/poly(3,4-ethylenedioxythiophene):poly(styrene sulfonate)/gold structure. The grating structures were fabricated on P3HT:PCBM layers using a nanoimprinting technique with a PDMS stamp. The grating-structured PDMS stamps were fabricated using a DVD-R grating template with a grating pitch, Λ, of 740 nm. Reflectivity measurements made using p-polarized light clearly indicate 2 types of excitation modes, i.e., surface plasmons and waveguide modes, while s-polarized light produces only waveguide modes. Incident photon-to-current efficiency measurements exhibited increased photocurrent wavelengths corresponding to the wavelengths of surface plasmon excitations and waveguide mode excitations. Through the simultaneous excitation of surface plasmons and waveguide modes, short-circuit photocurrents in the grating-structured cells exhibited an improvement of up to 11% in the solar cells, leading to an efficiency increase of 16%.
RESUMEN
Wilms tumor gene (WT1) protein is an attractive target for cancer immunotherapy. We aimed to investigate the feasibility of a combination therapy consisting of gemcitabine and WT1 peptide-based vaccine for patients with advanced pancreatic cancer and to make initial assessments of its clinical efficacy and immunologic response. Thirty-two HLA-A*24:02 patients with advanced pancreatic cancer were enrolled. Patients received HLA-A*24:02-restricted, modified 9-mer WT1 peptide (3 mg/body) emulsified with Montanide ISA51 adjuvant (WT1 vaccine) intradermally biweekly and gemcitabine (1000 mg/m) on days 1, 8, and 15 of a 28-day cycle. This combination therapy was well tolerated. The frequencies of grade 3-4 adverse events for this combination therapy were similar to those for gemcitabine alone. Objective response rate was 20.0% (6/30 evaluable patients). Median survival time and 1-year survival rate were 8.1 months and 29%, respectively. The association between longer survival and positive delayed-type hypersensitivity to WT1 peptide was statistically significant, and longer survivors featured a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes both before and after treatment. WT1 vaccine in combination with gemcitabine was well tolerated for patients with advanced pancreatic cancer. Delayed-type hypersensitivity-positivity to WT1 peptide and a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes could be useful prognostic markers for survival in the combination therapy with gemcitabine and WT1 vaccine. Further clinical investigation is warranted to determine the effectiveness of this combination therapy.